IL-8 receptor antagonists
First Claim
Patent Images
1. A compound selected from the group consisting of:
- N-{4-chloro-2-hydroxy-3-[(3S)-3-piperidinylsulfonyl]phenyl}-N′
-(3-fluoro-2-methylphenyl)urea;
N-[4-chloro-2-hydroxy-3-(3-piperidinylsulfonyl)-phenyl]-N′
-(3-fluoro-2-methylphenyl)urea;
N-{4-chloro-2-hydroxy-3-[(3S)-3-piperidinylsulfonyl]phenyl}-N′
-(2-chloro-3-pyridinyl)urea; and
N-(2-chloro-3-fluorophenyl)-N′
-{4-chloro-2-hydroxy-3-[(3S)-3-piperidinyl-sulfonyl]phenyl}urea;
or a pharmaceutically acceptable salt thereof.
2 Assignments
0 Petitions
Accused Products
Abstract
This invention relates to novel compounds and compositions thereof, useful in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).
-
Citations
31 Claims
-
1. A compound selected from the group consisting of:
-
N-{4-chloro-2-hydroxy-3-[(3S)-3-piperidinylsulfonyl]phenyl}-N′
-(3-fluoro-2-methylphenyl)urea;N-[4-chloro-2-hydroxy-3-(3-piperidinylsulfonyl)-phenyl]-N′
-(3-fluoro-2-methylphenyl)urea;N-{4-chloro-2-hydroxy-3-[(3S)-3-piperidinylsulfonyl]phenyl}-N′
-(2-chloro-3-pyridinyl)urea; andN-(2-chloro-3-fluorophenyl)-N′
-{4-chloro-2-hydroxy-3-[(3S)-3-piperidinyl-sulfonyl]phenyl}urea;or a pharmaceutically acceptable salt thereof. - View Dependent Claims (2, 3, 4, 5, 6, 15, 19, 22)
-
-
7. The compound which is N-{4-chloro-2-hydroxy-3-[(3S)-3-piperidinylsulfonyl]phenyl}-N′
- -(3-fluoro-2-methylphenyl)urea, or a pharmaceutically acceptable salt thereof.
- View Dependent Claims (16, 20)
-
8. A pharmaceutical composition comprising N-{4-chloro-2-hydroxy-3-[(3S)-3-piperidinylsulfonyl]phenyl}-N′
- -(3-fluoro-2-methylphenyl)urea, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent.
-
9. The compound which is N-{4-chloro-2-hydroxy-3-[(3S)-3-piperidinylsulfonyl]phenyl}-N′
- -(3-fluoro-2-methylphenyl)urea.
- View Dependent Claims (21)
-
10. A pharmaceutical composition comprising N-{4-chloro-2-hydroxy-3-[(3S)-3-piperidinylsulfonyl]phenyl}-N′
- -(3-fluoro-2-methylphenyl)urea and a pharmaceutically acceptable carrier or diluent.
-
11. The compound which is N-(2-chloro-3-fluorophenyl)-N′
- -{4-chloro-2-hydroxy-3-[(3S)-3-piperidinylsulfonyl]phenyl}urea, or a pharmaceutically acceptable salt thereof.
- View Dependent Claims (18)
-
12. A pharmaceutical composition comprising N-(2-chloro-3-fluorophenyl)-N′
- -{4-chloro-2-hydroxy-3-[(3S)-3-piperidinylsulfonyl]phenyl}urea, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent.
-
13. The compound which is N-(2-chloro-3-fluorophenyl)-N′
- -{4-chloro-2-hydroxy-3-[(3S)-3-piperidinylsulfonyl]phenyl}urea.
-
14. A pharmaceutical composition comprising N-(2-chloro-3-fluorophenyl)-N′
- -{4-chloro-2-hydroxy-3-[(3S)-3-piperidinylsulfonyl]phenyl}urea and a pharmaceutically acceptable carrier or diluent.
-
17. The compound which is N-[4-chloro-2-hydroxy-3-(3-piperidinylsulfonyl)-phenyl]-N′
- -(3-fluoro-2-methylphenyl)urea, or a pharmaceutically acceptable salt thereof.
- View Dependent Claims (24, 28, 29)
-
23. A pharmaceutical composition comprising N-{4-chloro-2-hydroxy-3-[(3S)-3-piperidinylsulfonyl]phenyl}-N′
- -(3-fluoro-2-methylphenyl)urea, or a pharmaceutically acceptable salt thereof, or N-[4-chloro-2-hydroxy-3-(3-piperidinylsulfonyl)-phenyl]-N′
-(3-fluoro-2-methylphenyl)urea, or a pharmaceutically acceptable salt thereof, in admixture with a pharmaceutically acceptable carrier or diluent for administration by intravenous, intramuscular, subcutaneous, intravaginal, intraperitoneal, oral inhalation, or intranasal means.
- -(3-fluoro-2-methylphenyl)urea, or a pharmaceutically acceptable salt thereof, or N-[4-chloro-2-hydroxy-3-(3-piperidinylsulfonyl)-phenyl]-N′
-
25. The compound which is N-[4-chloro-2-hydroxy-3-(3-piperidinylsulfonyl)-phenyl]-N′
- -(3-fluoro-2-methylphenyl)urea.
- View Dependent Claims (30, 31)
-
26. A pharmaceutical composition comprising N-[4-chloro-2-hydroxy-3-(3-piperidinylsulfonyl)-phenyl]-N′
- -(3-fluoro-2-methylphenyl)urea, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent.
-
27. A pharmaceutical composition comprising N-[4-chloro-2-hydroxy-3-(3-piperidinylsulfonyl)-phenyl]-N′
- -(3-fluoro-2-methylphenyl)urea, and a pharmaceutically acceptable carrier or diluent.
Specification